Denali Therapeutics Inc.

NASDAQ: DNLI
Share price (8/14/25): $14.46
Market cap (8/14/25): $2.114 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024

ended 09/30/24 Q3

ended 06/30/24 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Automatic shelf registration

Automatic shelf registration

Exempt offering of securities

Registration of securities for employees

Ownership Filter

Schuth Alexander O.

Schuth Alexander O.

News Filter

Reports Second Quarter 2025 Financial Results and Business Highlights

Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome

Material Definitive Agreement, Shareholder Vote Results, Financial Statements or Exhibits

Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions With FDA on DNL126 Through START Program

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Letter from the SEC

Correspondence with the SEC